Fiche publication
Date publication
mai 2019
Journal
Allergy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr JANKOWSKI Roger
Tous les auteurs :
Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, Canonica GW, Deneyer L, Desrosiers M, Diamant Z, Han J, Heffler E, Hopkins C, Jankowski R, Joos G, Knill A, Lee JT, Lee SE, Mariën G, Pugin B, Senior B, Seys SF, Hellings PW
Lien Pubmed
Résumé
Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent co-morbidities, ensuring alleviation of both upper and lower airway pathology by systemic biologic therapy. Type 2 targeting biologics such as anti-IgE, anti- IL4Rα, anti-IL5 and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma. This article is protected by copyright. All rights reserved.
Mots clés
asthma, biologics, care pathways, chronic rhinosinusitis, nasal polyps, type 2 inflammation
Référence
Allergy. 2019 May 15;:
